Ligand Pharmaceuticals Incorporated

Healthcare · Biotechnology

301.50$ +0.8% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Balance Sheet

Ligand Pharmaceuticals Incorporated (LGND) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 1,561 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet LGND
Line item	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	102	107	156	135	113	117	271	301	332	315	326	173	171	114	76	122	104	105	258	534	602	671	1,261	1,495	1,362	1,298	763	787	942	1,561
Current Assets	85	84	78	57	45	54	84	130	173	133	236	110	94	68	37	32	24	25	185	216	163	237	871	1,124	501	465	264	237	332	832
Cash	35	62	33	30	9.2	21	42	59	92	67	158	77	29	16	3.3	7.0	12	16	167	200	141	202	718	72	48	20	45	23	72	175
Cash & Short-Term Investments	35	62	33	47	24	38	64	99	–	87	172	94	81	53	23	17	12	16	167	200	141	202	765	1,070	411	341	212	170	256	734
Receivables	3.1	–	–	1.7	13	9.8	7.4	19	31	21	16	14	12	10	14	12	8.9	6.6	14	12	18	29	56	42	59	92	35	39	42	61
Inventory	–	–	6.2	5.7	5.7	3.8	4.8	8.3	12	9.3	3.9	-10	1.1	-53	-23	1.3	1.7	1.4	0.3	1.6	1.9	4.4	7.1	7.3	26	27	13	24	14	9.1
Property, Plant & Equipment	–	–	–	–	11	9.7	9.7	24	24	22	5.6	2.9	13	8.5	0.6	0.5	0.8	0.9	0.9	0.4	1.8	4.2	5.4	7.2	14	33	27	–	–	–
Goodwill	–	–	–	–	–	–	–	–	–	–	–	–	5.4	0.7	0.7	15	68	65	63	61	277	315	306	95	190	106	106	103	105	102
Intangible Assets	–	–	–	–	45	42	149	138	127	147	83	–	5.4	2.5	13	57	56	4.6	4.6	8.6	26	20	31	231	606	387	353	300	267	422
Total Liabilities	68	73	167	160	169	175	197	231	408	425	299	144	182	110	83	114	78	55	234	230	231	252	700	728	653	476	165	86	111	543
Current Liabilities	14	22	27	21	28	32	31	54	217	235	171	51	71	52	36	44	35	29	23	21	227	239	82	17	100	42	99	17	37	37
Short-Term Debt	2.6	2.8	3.2	4.1	3.5	5.4	2.1	2.5	2.9	2.7	38	1.5	3.7	0.1	8.0	10	15	9.1	0.3	202	213	225	26	1.3	8.5	1.4	77	0.4	1.3	1.1
Accounts Payable	4.1	11	12	5.4	3.8	5.4	12	19	17	15	12	13	15	17	8.6	11	16	16	7.7	4.1	9.1	9.6	4.2	2.4	3.8	8.4	5.3	2.4	5.2	3.2
Long-Term Debt	–	–	–	–	132	137	159	170	171	170	2.2	0.6	2.2	–	–	20	19	0.0	3.1	40	30	19	610	639	442	321	–	–	–	446
Shareholders' Equity	35	34	-11	-26	-55	-58	74	71	-75	-110	27	29	-10	3.7	-7.0	8.6	26	50	26	304	371	419	561	767	710	821	597	701	830	1,017
Retained Earnings	-178	-278	-396	-470	-543	-586	-618	-656	-795	-831	-863	-582	-680	-682	-692	-682	-683	-671	-659	-402	-431	-401	-229	400	392	449	451	503	499	608
Shares Outstanding	4.8	5.5	6.7	7.9	9.3	9.9	12	12	12	12	13	16	16	19	20	20	20	21	21	21	21	23	24	20	16	17	17	18	18	20

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings